查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1490320

超級仿製藥市場：產業趨勢與全球預測（-2035）：依治療領域、給藥途徑、分子類型、小分子類型、產品類型和主要地理區域

Super Generics Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Therapeutic Area, Route of Administration, Type of Molecule, Type of Small Molecule, Type of Product and Key Geographical Regions
出版日期: | 出版商: Roots Analysis | 英文 257 Pages | 商品交期: 最快1-2個工作天內

價格

超級仿製藥市場預計到 2024 年將價值 840 億美元，並在 2024-2035 年預測期間以 8% 的複合年增長率擴張。

在製藥領域，超級仿製藥是指失去專利獨佔性的品牌藥的改良版本。這些複雜的藥理學幹預措施通常被稱為複雜仿製藥或增值仿製藥，並充當品牌藥物的仿製藥替代品。值得注意的是，美國FDA在2022年核准了超過32,000種仿製藥，美國91%的處方藥都是仿製藥。這些改良的超仿製藥有潛力推進藥物傳輸、製造流程和重新配製技術。這個增值領域在持續技術創新的框架內運作，為製藥市場提供了充滿希望的機會。超級仿製藥通常被授予三到七年的獨佔權，使開發商能夠獲得比傳統仿製藥相對更高的利潤率。 FDA（美國）和 EMA（歐洲）等監管機構對這些藥物進行審查並批准它們進入超級仿製藥市場。

開發超級仿製藥需要嚴格的研發，以確保安全性、有效性和品質。產業利害關係人正在投資廣泛的臨床前和臨床試驗，以建立與參考原廠藥的生物等效性和治療等效性。隨著世界各地監管機構批准更多仿製藥，預計該行業的競爭將會加劇。競爭加劇的主要結果是仿製藥成本降低，開發仿製藥公司的利潤率降低。因此，為了維持非專利藥物市場的成長，企業逐漸採用創新的藥物修飾技術來創造具有更好商業前景的加值藥物。零售藥局和網路藥局提供多種仿製藥，降低了消費者的醫療費用。此外，在許多歐洲國家，藥劑師有權以仿製藥取代品牌處方藥，除非醫療保健提供者另有規定。

本報告調查了全球超仿製藥市場，並提供了市場概況以及依治療領域、給藥途徑、分子類型、小分子類型、產品類型、主要區域劃分的趨勢，並提供了公司概況進入市場等

目錄

第一章前言

第二章研究方法

第 3 章經濟與其他專案特定考量

第 4 章執行摘要

第 5 章簡介

第六章超級仿製藥：市場現況

  • 章節概述
  • 超級仿製藥：市場狀況

第 7 章超通用技術：市場狀況

  • 章節概述
  • 超通用技術：市場狀況
  • 超通用技術開發商

第八章技術競爭分析

  • 章節概述
  • 調查方法及主要參數
  • 科技由北美公司提供
  • 科技由歐洲公司提供
  • 科技由亞太地區的公司提供

第九章公司簡介

  • 章節概述
  • Ascendia Pharmaceuticals
  • CritiTech
  • Crossject
  • DelSiTech
  • Heron Therapeutics
  • Latitude Pharmaceuticals
  • Mayne Pharma
  • Neurelis
  • Rubicon Research
  • Taiwan Liposome Company
  • tesa Labtec

第 10 章案例研究：核准的超級仿製藥

  • 章節概述
  • 奧斯特 (R)
  • Abraxane (R)
  • 艾維庫斯 (R)
  • Prosisvi(R)
  • Trokendi XR (R)

第 11 章超級仿製藥：有前途的候選藥物

  • 章節概述
  • 上市的候選藥物

第十二章 SWOT 分析

第十三章全球超級仿製藥市場

  • 章節概述
  • 主要假設與研究方法
  • 超級仿製藥市場整體、過去趨勢（2018-2022）與預測（2023-2035）
  • 超級仿製藥市場：依治療領域劃分，2023-2035 年
  • 超級仿製藥市場：依給藥途徑劃分，2023-2035 年
  • 超級仿製藥市場：依分子類型，2023-2035 年
  • 超級仿製藥市場：以小分子類型劃分，2023-2035 年
  • 超級仿製藥市場：依產品類型劃分，2023-2035 年
  • 超級仿製藥市場：依地區劃分，2023-2035 年

第14章結論

第 15 章附錄 1：表格資料

第十六章附錄二：公司與組織名單

Product Code: RA100483

Super Generics Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Therapeutic Area (Cardiovascular Disorders, Metabolic Disorders, Neurological Disorders, Oncological Disorders, Respiratory Disorders and Other Disorders), Route of Administration (Intravenous, Oral, Subcutaneous and Others), Type of Molecule (Small and Other Molecules), Type of Small Molecule (Generics and Other Small Molecules), Type of Product (Aerosols, Capsules, Prefilled Syringes, Tablets, Vials and Other Products) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World)

The Super Generics Market is valued at USD 84 billion in 2024 growing at a CAGR of 8% during the forecast period 2024-2035.

In the pharmaceutical domain the super generic drugs represent the enhanced versions of original pharmaceuticals that have lost their patent exclusivity. These refined pharmacological interventions are often termed as complex generics or value-added generics and serve as generic alternatives to their branded counterparts. Notably, in 2022, the US FDA sanctioned over 32,000 generic drug products, with 91% of all US prescriptions being filled with generics. These improved super generics hold the potential for advancements in drug delivery, manufacturing processes, and reformulation techniques. This value-added segment operates within a framework of ongoing innovation, offering promising opportunities in the pharmaceutical market. Super generic drugs are granted a form of marketing exclusivity, typically for 3 to 7 years, allowing developers to achieve relatively high profit margins as compared to the conventional generics. Regulatory bodies such as the FDA (in the US) or the EMA (in Europe) scrutinize these drugs and grant approval for their entry in the super generics market.

Developing super generic drugs entails rigorous research and development to ensure their safety, efficacy, and quality. Industry stakeholders invest in extensive preclinical and clinical studies to establish bioequivalence or therapeutic equivalence with the reference brand-name drug. As regulatory agencies worldwide greenlight more generic drugs, competition in the industry is expected to intensify. The primary consequence of this heightened competition is a decrease in the cost of generics, leading to reduced profit margins for developers. Hence, to sustain growth in the off-patent drug market, companies are progressively adopting innovative drug alteration techniques to create value-added medicinal products with better commercial prospects. Retail and online pharmacies offer a wide array of generic options, empowering consumers to lower healthcare expenses. Moreover, in numerous European countries, pharmacists have the authority to substitute brand-name prescriptions with generic equivalents unless otherwise specified by healthcare. providers.

Key Market Segments

Therapeutic Area

  • Cardiovascular Disorders
  • Metabolic Disorders
  • Neurological Disorders
  • Oncological Disorders
  • Respiratory Disorders
  • Other Disorders

Route of Administration

  • Intravenous
  • Oral
  • Subcutaneous
  • Others

Type of Molecule

  • Small
  • Other Molecules

Type of Small Molecule

  • Generics
  • Other Small Molecule

Type of Product

  • Aerosols
  • Capsules
  • Prefilled Syringes
  • Tablets
  • Vials
  • Other Products

Geography

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Research Coverage:

  • A summary of super generics technologies, including details on various pertinent parameters such as the type of drug modification, technology type, molecules formulated/delivered, route of administration, and type of value addition. This encompasses information on technology providers offering platforms/solutions for super generic drug development, including their year of establishment, company size (in terms of the number of employees), and headquarters location.
  • An insightful analysis of the competitiveness of the technologies compiled in our database, considering pertinent parameters including supplier power (based on the company size of technology providers) and technology competitiveness, such as the type of molecule, impact on drug properties, and route of administration.
  • Detailed profiles of prominent technology developers involved in this domain are provided, offering an overview of the company, its financial information where available, technology portfolio, recent advancements, and future outlook.
  • A compilation of marketed generics that, in our assessment, are poised to be developed as super generics in the near future, derived from a thorough analysis considering various pertinent parameters. These parameters include the current annual cost of treatment of the parent drug, year of patent expiry, sales revenues generated in the year prior to patent expiry, target therapeutic area, and the number of competitor (generic) drugs available in the market.
  • Comprehensive case studies are presented for five approved supergeneric drugs, encompassing an overview of the drug along with details on the original/parent drug, the value proposition offered by the supergeneric version, pricing strategies adopted by the developer where available, annual sales revenues of the supergeneric and parent drug if available, and key learnings/takeaways from each case study.
  • A discourse on associated trends, key drivers, and challenges within a SWOT framework, which are anticipated to influence the evolution of the industry, accompanied by a Harvey ball analysis to illustrate the relative impact of each SWOT parameter on the overall super generics market.
  • A thorough assessment of the current market size, existing opportunity, and the future growth potential of the super generics market over the next decade is conducted. Drawing from various parameters, including likely adoption trends, we have formulated an informed estimate on the market evolution during the forecast period from 2024 to 2035. The report also includes an analysis of the likely distribution of current and forecasted opportunities within the super generics market. Additionally, to accommodate future uncertainties and enhance the robustness of our model, three forecast scenarios-conservative, base, and optimistic-are provided, representing different trajectories of growth in the super generics market.

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the Super Generics Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

  • Accord Healthcare
  • Alcon Laboratories
  • Ascendia Pharmaceuticals
  • Azurity Pharmaceuticals
  • Baxter
  • CritiTech
  • Crossject
  • DelSiTech
  • Dr. Reddy's Laboratories
  • Exela Pharma Sciences
  • Harrow Health
  • Heron Therapeutics
  • Hikma Pharmaceuticals
  • Intellipharmaceutics International
  • Kashiv BioSciences
  • Latitude Pharmaceuticals
  • Mayne Pharma
  • meda pharmaceuticals
  • Neurelis
  • Rubicon Research
  • Sun Pharmaceutical industries
  • Taiwan Liposome Company
  • Tesa Labtec
  • Teva Pharmaceutical

TABLE OF CONTENTS

Table Of Contents

1. PREFACE

  • 1.1 Introduction
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact / Related Factors
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Forecasted Estimates
    • 3.2.2. Currency Coverage
      • 3.2.2.1. Overview of Major Currencies Affecting the Market
      • 3.2.2.2. Impact of Currency Fluctuations on the Industry
    • 3.2.3. Foreign Exchange Impact
      • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Overview of Generic Drugs
    • 5.2.1. Key Challenges within the Generics Industry
      • 5.2.1.1. Policy Changes
      • 5.2.1.2. Increasing Competition
      • 5.2.1.3. Price Erosion
  • 5.3. Super Generics
    • 5.3.1. Techniques Used for the Development of Super Generics
    • 5.3.2. Regulatory Pathways for Approval of Super Generics
  • 5.4. Advantages of Super Generics
    • 5.4.1. Improved Efficacy
    • 5.4.2. Increased IP Protection
    • 5.4.3. Cost and Time Efficient Development Process
  • 5.5. Challenges Related to Super Generics
  • 5.6. Future Perspectives

6. SUPER GENERIC DRUGS: MARKET LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Super Generic Drugs: Overall Market Landscape
    • 6.2.1. Analysis by Route of Administration
    • 6.2.2. Analysis by Target Indication
    • 6.2.3. Analysis by Target Therapeutic Area
    • 6.2.4. Analysis by Submission Classification Code
    • 6.2.5. Most Active Players: Analysis by Number of Super Generic Drugs

7. SUPER GENERIC TECHNOLOGIES: MARKET LANDSCAPE

  • 7.1 Chapter Overview
  • 7.2. Super Generic Technologies: Overall Market Landscape
    • 7.2.1 Analysis by Type of Drug Modification
    • 7.2.2 Analysis by Type of Technology
    • 7.2.3 Analysis by Type of Molecules Formulated / Delivered
    • 7.2.4 Analysis by Route of Administration
    • 7.2.5 Analysis by Type of Value Addition
  • 7.3. Super Generics Technology Developers
    • 7.3.1 Analysis by Year of Establishment
    • 7.3.2 Analysis by Company Size
    • 7.3.3 Analysis by Location of Headquarters (Region)
    • 7.3.4. Most Active Players: Analysis by Number of Super Generics Technologies

8. TECHNOLOGY COMPETITIVENESS ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Methodology and Key Parameters
  • 8.3. Technologies Offered by Companies based in North America
    • 8.3.1 Technologies Offered by Companies based in North America (Peer Group I)
    • 8.3.2 Technologies Offered by Companies based in North America (Peer Group II)
  • 8.4 Technologies Offered by Companies based in Europe
  • 8.5. Technologies Offered by Companies based in Asia-Pacific

9. COMPANY PROFILES

  • 9.1. Chapter Overview
  • 9.2. Ascendia Pharmaceuticals
    • 9.2.1. Company Overview
    • 9.2.2. Technology Portfolio
      • 9.2.2.1. NanoSol
      • 9.2.2.2. AmorSol
      • 9.2.2.3. EmulSol
    • 9.2.3. Recent Developments and Future Outlook
  • 9.3. CritiTech
    • 9.3.1. Company Overview
    • 9.3.2. Technology Portfolio
      • 9.3.2.1. Spray Drying Technology
      • 9.3.2.2. Supercritical Precipitation Technology
    • 9.3.3. Recent Developments and Future Outlook
  • 9.4. Crossject
    • 9.4.1. Company Overview
    • 9.4.2. Technology Portfolio
      • 9.4.2.1. ZENEO(R)
    • 9.4.3. Recent Developments and Future Outlook
  • 9.5. DelSiTech
    • 9.5.1. Company Overview
    • 9.5.2. Technology Portfolio
      • 9.5.2.1. DelSiTech(TM) Silica
    • 9.5.3. Recent Developments and Future Outlook
  • 9.6. Heron Therapeutics
    • 9.6.1. Company Overview
    • 9.6.2. Technology Portfolio
      • 9.6.2.1. Biochronomer(R)
    • 9.6.3. Recent Developments and Future Outlook
  • 9.7. Latitude Pharmaceuticals
    • 9.7.1. Company Overview
    • 9.7.2. Technology Portfolio
      • 9.7.2.1. Nano-E(TM)
      • 9.7.2.2. PG-Depot(TM)
      • 9.7.2.3. ARTSS(TM)
      • 9.7.2.4. RFAP(TM) Matrix
      • 9.7.2.5. RTTS
      • 9.7.2.6. 24H(TM)
      • 9.7.2.7. MiniSpheres
      • 9.7.2.8. GelPatch
    • 9.7.3. Recent Developments and Future Outlook
  • 9.8. Mayne Pharma
    • 9.8.1. Company Overview
    • 9.8.2. Financial Information
    • 9.8.3. Technology Portfolio
      • 9.8.3.1. SUBA(TM)
      • 9.8.3.2. Cleantaste(TM)
      • 9.8.3.3. Pellet Technology
    • 9.8.4. Recent Developments and Future Outlooks
  • 9.9. Neurelis
    • 9.9.1. Company Overview
    • 9.9.2. Technology Portfolio
      • 9.9.2.1. Intravail(R)
      • 9.9.2.2. ProTek(R)
      • 9.9.2.3. Hydrogel(TM)
    • 9.9.3. Recent Developments and Future Outlook
  • 9.10. Rubicon Research
    • 9.10.1. Company Overview
    • 9.10.2. Technology Portfolio
      • 9.10.2.1. RubiERT(R)
      • 9.10.2.2. RubiDT(R)
      • 9.10.2.3. RubiReten(R)
      • 9.10.2.4. RubiSRL(R)
  • 9.11. Taiwan Liposome Company
    • 9.11.1. Company Overview
    • 9.11.2. Financial Information
    • 9.11.3. Technology Portfolio
      • 9.11.3.1. BioSeizer(R)
      • 9.11.3.2. NanoX(TM)
      • 9.11.3.3. Polymeric Micelle
    • 9.11.4. Recent Developments and Future Outlook
  • 9.12. tesa Labtec
    • 9.12.1. Company Overview
    • 9.12.2. Technology Portfolio
      • 9.12.2.1. Transfilm(R)
      • 9.12.2.2. Mucofilm(R)
      • 9.12.2.3. Rapidfilm(R)
    • 9.12.3. Recent Developments and Future Outlook

10 CASE STUDY: APPROVED SUPER GENERIC DRUGS

  • 10.1. Chapter Overview
  • 10.2. Austedo(R)
    • 10.2.1. Overview
    • 10.2.2. Originator Drug Overview
    • 10.2.3. Value Proposition
    • 10.2.4. Financial Information
    • 10.2.5. Key Learnings
  • 10.3. Abraxane(R)
    • 10.3.1. Overview
    • 10.3.2. Originator Drug Overview
    • 10.3.3. Value Proposition
    • 10.3.4. Financial Information
    • 10.3.5. Key Learnings
  • 10.4. Avycaz(R)
    • 10.4.1. Overview
    • 10.4.2. Originator Drug Overview
    • 10.4.3. Value Proposition
    • 10.4.4. Financial Information
    • 10.4.5. Key Learnings
  • 10.5. Procysbi(R)
    • 10.5.1. Overview
    • 10.5.2. Originator Drug Overview
    • 10.5.3. Value Proposition
    • 10.5.4. Financial Information
    • 10.5.5. Key Learnings
  • 10.6. Trokendi XR(R)
    • 10.6.1. Overview
    • 10.6.2. Originator Drug Overview
    • 10.6.3. Value Proposition
    • 10.6.4. Financial Information
    • 10.6.5. Key Learnings

11. SUPER GENERICS: LIKELY DRUG CANDIDATES

  • 11.1. Chapter Overview
  • 11.2. Marketed Drug Candidates
    • 11.2.1. Most Likely Drug Candidates for Super Generics
    • 11.2.2. Likely Drug Candidates for Super Generics
    • 11.2.3. Less Likely Drug Candidates for Super Generics
    • 11.2.4. Least Likely Drug Candidates for Super Generics

12. SWOT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Strengths
  • 12.3. Weakness
  • 12.4. Opportunities
  • 12.5. Threats
  • 12.6. Concluding Remarks

13. GLOBAL SUPER GENERICS MARKET

  • 13.1. Chapter Overview
  • 13.2. Key Assumptions and Methodology
  • 13.3. Overall Super Generics Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 13.4. Super Generics Market: Distribution by Therapeutic Area, 2023-2035
  • 13.5. Super Generics Market: Distribution by Route of Administration, 2023-2035
  • 13.6. Super Generics Market: Distribution by Type of Molecule, 2023-2035
  • 13.7. Super Generics Market: Distribution by Type of Small Molecule, 2023-2035
  • 13.8. Super Generics Market: Distribution by Type of Product, 2023-2035
  • 13.9. Super Generics Market: Distribution by Geography, 2023-2035
    • 13.9.1. Super Generics Market in North America, 2023-2035
      • 13.9.1.1. Super Generics Market in North America: Distribution by Therapeutic Area, 2023-2035
        • 13.9.1.1.1. Super Generics Market for Oncological Disorders in North America, 2023-2035
        • 13.9.1.1.2. Super Generics Market for Metabolic Disorders in North America, 2023-2035
        • 13.9.1.1.3. Super Generics Market for Neurological Disorders in North America, 2023-2035
        • 13.9.1.1.4. Super Generics Market for Respiratory Disorders in North America, 2023-2035
        • 13.9.1.1.5. Super Generics Market for Cardiovascular Disorders in North America, 2023-2035
        • 13.9.1.1.6. Super Generics Market for Other Disorders in North America, 2023-2035
      • 13.9.1.2. Super Generics Market: Distribution by Route of Administration in North America
        • 13.9.1.2.1. Super Generics Market for Oral Route of Administration in North America, 2023-2035
      • 13.9.12.2. Super Generics Market for Subcutaneous Route of Administration in North America, 2023-2035
        • 13.9.1.2.3. Super Generics Market for Intravenous Route of Administration in North America, 2023-2035
        • 13.9.1.2.4. Super Generics Market for Other Routes of Administration in North America, 2023-2035
      • 13.9.1.3. Super Generics Market: Distribution by Type of Molecule in North America
        • 13.9.1.3.1. Super Generics Market for Small Molecule in North America, 2023-2035
        • 13.9.1.3.2. Super Generics Market for Biologics in North America, 2023-2035
      • 13.9.1.4. Super Generics Market: Distribution by Type of Small Molecules in North America
        • 13.9.1.4.1 Super Generics Market for Complex Generics in North America, 2023-2035
        • 13.9.1.4.2. Super Generics Market for Other Small Molecules in North America, 2023-2035
      • 13.9.1.5. Super Generics Market: Distribution by Type of Product Offered in North America
        • 13.9.1.5.1. Super Generics Market for Prefilled Syringe in North America, 2023-2035
        • 13.9.1.5.2. Super Generics Market for Vials in North America, 2023-2035
        • 13.9.1.5.3. Super Generics Market for Aerosols in North America, 2023-2035
        • 13.9.1.5.4. Super Generics Market for Tablets in North America, 2023-2035
        • 13.9.1.5.5. Super Generics Market for Capsules in North America, 2023-2035
        • 13.9.1.5.6. Super Generics Market for Other Types of Products in North America, 2023-2035
    • 13.9.2. Super Generics Market in Europe, 2023-2035
      • 13.9.2.1. Super Generics Market in Europe: Distribution by Therapeutic Area, 2023-2035
        • 13.9.2.1.1. Super Generics Market for Oncological Disorders in Europe, 2023-2035
        • 13.9.2.1.2. Super Generics Market for Metabolic Disorders in Europe, 2023-2035
        • 13.9.2.1.3. Super Generics Market for Neurological Disorders in Europe, 2023-2035
        • 13.9.2.1.4. Super Generics Market for Respiratory Disorders in Europe, 2023-2035
        • 13.9.2.1.5. Super Generics Market for Cardiovascular Disorders in Europe, 2023-2035
        • 13.9.2.1.6. Super Generics Market for Other Disorders in Europe, 2023-2035
      • 13.9.2.2. Super Generics Market Distribution by Route of Administration in Europe
        • 13.9.2.2.1. Super Generics Market for Oral Route of Administration in Europe, 2023-2035
        • 13.9.2.2.2. Super Generics Market for Subcutaneous Route of Administration in Europe, 2023-2035
        • 13.9.2.2.3. Super Generics Market for Intravenous Route of Administration in Europe, 2023-2035
        • 13.9.2.2.4. Super Generics Market for Other Routes of Administration in Europe, 2023-2035
      • 13.9.2.3. Super Generic Drugs Market: Distribution by Type of Molecule in Europe
        • 13.9.2.3.1. Super Generic Drugs Market for Small Molecule in Europe, 2023-2035
        • 13.9.2.3.2. Super Generic Drugs Market for Biologics in Europe, 2023-2035
      • 13.9.2.4. Super Generic Drugs Market: Distribution by Type of Small Molecules in Europe
        • 13.9.2.4.1 Super Generic Drugs Market for Complex Generics in Europe, 2023-2035
        • 13.9.2.4.2. Super Generics Market for Other Small Molecules in Europe, 2023-2035
      • 13.9.2.5. Super Generic Market: Distribution by Type of Product Offered in Europe
        • 13.9.2.5.1. Super Generic Market for Prefilled Syringe in Europe, 2023-2035
        • 13.9.2.5.2. Super Generic Market for Vials in Europe, 2023-2035
        • 13.9.2.5.3. Super Generic Market for Aerosols in Europe, 2023-2035
        • 13.9.2.5.4. Super Generic Market for Tablets in Europe, 2023-2035
        • 13.9.2.5.5. Super Generic Market for Capsules in Europe, 2023-2035
        • 13.9.2.5.6. Super Generics Market for Other Types of Products in Europe, 2023-2035
    • 13.9.3. Super Generics Market in Asia-Pacific, 2023-2035
      • 13.9.3.1. Super Generics Market in Asia-Pacific: Distribution by Therapeutic Area, 2023-2035
        • 13.9.3.1.1. Super Generics Market for Oncological Disorders in Asia-Pacific, 2023-2035
        • 13.9.3.1.2. Super Generics Market for Metabolic Disorders in Asia-Pacific, 2023-2035
        • 13.9.3.1.3. Super Generics Market for Neurological Disorders in Asia-Pacific, 2023-2035
        • 13.9.3.1.4. Super Generics Market for Respiratory Disorders in Asia-Pacific, 2023-2035
        • 13.9.3.1.5. Super Generics Market for Cardiovascular Disorders in Asia-Pacific, 2023-2035
        • 13.9.3.1.6. Super Generics Market for Other Disorders in Asia-Pacific, 2023-2035
      • 13.9.3.2. Super Generics Market Distribution by Route of Administration in Asia-Pacific
        • 13.9.3.2.1. Super Generics Market for Oral Route of Administration in Asia-Pacific, 2023-2035
        • 13.9.3.2.2. Super Generics Market for Subcutaneous Route of Administration in Asia-Pacific, 2023-2035
        • 13.9.3.2.3. Super Generics Market for Intravenous Route of Administration in Asia-Pacific, 2023-2035
        • 13.9.4.2.4. Super Generics Market for Other Routes of Administration in Asia-Pacific, 2023-2035
      • 13.9.3.3. Super Generics Market: Distribution by Type of Molecule in Asia-Pacific
        • 13.9.3.3.1. Super Generics Market for Small Molecule in Asia-Pacific, 2023-2035
        • 13.9.3.3.2. Super Generics Market for Biologics in Asia-Pacific, 2023-2035
      • 13.9.3.4. Super Generics Market: Distribution by Type of Small Molecules in Asia-Pacific
        • 13.9.3.4.1 Super Generics Market for Complex Generics in Asia-Pacific, 2023-2035
        • 13.9.3.4.2. Super Generics Market for Other Small Molecules in Asia-Pacific, 2023-2035
      • 13.9.3.5. Super Generics Market: Distribution by Type of Product Offered in Asia-Pacific
        • 13.9.3.5.1. Super Generics Market for Prefilled Syringe in Asia-Pacific, 2023-2035
        • 13.9.3.5.2. Super Generics Market for Vials in Asia-Pacific, 2023-2035
        • 13.9.3.5.3. Super Generics Market for Aerosols in Asia-Pacific, 2023-2035
        • 13.9.3.5.4. Super Generics Market for Tablets in Asia-Pacific, 2023-2035
        • 13.9.3.5.5. Super Generics Market for Capsules in Asia-Pacific, 2023-2035
        • 13.9.3.5.6. Super Generics Market for Other Types of Products in Asia-Pacific, 2023-2035
    • 13.9.4. Super Generics Market in Rest of the World, 2023-2035
      • 13.9.4.1. Super Generics Market in Rest of the World: Distribution by Therapeutic Area, 2023-2035
        • 13.9.4.1.1. Super Generics Market for Oncological Disorders in Rest of the World, 2023-2035
        • 13.9.4.1.2. Super Generics Market for Metabolic Disorders in Rest of the World, 2023-2035
        • 13.9.4.1.3. Super Generics Market for Neurological Disorders in Rest of the World, 2023-2035
        • 13.9.4.1.4. Super Generics Market for Respiratory Disorders in Rest of the World, 2023-2035
        • 13.9.4.1.5. Super Generics Market for Cardiovascular Disorders in Rest of the World, 2023-2035
        • 13.9.4.1.6. Super Generics Market for Other Disorders in Rest of the World, 2023-2035
      • 13.9.4.2. Super Generics Market Distribution by Route of Administration in Rest of the World
        • 13.9.4.2.1. Super Generics Market for Oral Route of Administration in Rest of the World, 2023-2035
        • 13.9.4.2.2. Super Generics Market for Subcutaneous Route of Administration in Rest of the World, 2023-2035
        • 13.9.4.2.3. Super Generics Market for Intravenous Route of Administration in Rest of the World, 2023-2035
        • 13.9.4.2.4. Super Generics Market for Other Routes of Administration in Rest of the World, 2023-2035
      • 13.9.4.3. Super Generics Market: Distribution by Type of Molecule in Rest of the World
        • 13.9.4.3.1. Super Generics Market for Small Molecule in Rest of the World, 2023-2035
        • 13.9.4.3.2. Super Generics Market for Biologics in Rest of the World, 2023-2035
      • 13.9.4.4. Super Generics Market: Distribution by Type of Small Molecules in Rest of the World
        • 13.9.4.4.1 Super Generics Market for Complex Generics in Rest of the World, 2023-2035
        • 13.9.4.4.2. Super Generics Market for Other Small Molecules in Rest of the World, 2023-2035
      • 13.9.4.5. Super Generics Market: Distribution by Type of Product Offered in Rest of the World
        • 13.9.4.5.1. Super Generics Market for Prefilled Syringe in Rest of the World, 2023-2035
        • 13.9.4.5.2. Super Generics Market for Vials in Rest of the World, 2023-2035
        • 13.9.4.5.3. Super Generics Market for Aerosols in Rest of the World, 2023-2035
        • 13.9.4.5.4. Super Generics Market for Tablets in Rest of the World, 2023-2035
        • 13.9.4.5.5. Super Generics Market for Capsules in Rest of the World, 2023-2035
        • 13.9.4.5.6. Super Generics Market for Other Types of Products in Rest of the World, 2023-2035

14. CONCLUSION

15. APPENDIX 1: TABULATED DATA

16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 5.1 Different Nomenclatures Used for Value-added Generics
  • Table 5.2 Comparison of FDA Drug Approval Pathways
  • Table 5.3 Market Exclusivity Period for Different Submission Classifications
  • Table 5.4 Comparison of Drug Development Timeline
  • Table 6.1 Super Generic Drugs: List of FDA Approved Drugs, 2016-2024
  • Table 6.2 Super Generic Drugs: Additional Details, 2016-2024
  • Table 7.1 Super Generic Technologies: Information on Type of Drug Modification and Type of Technology
  • Table 7.2 Super Generic Technologies: Information on Type of Molecule, Route of Administration and Type of Value Addition
  • Table 7.3 Super Generic Technologies: List of Developers
  • Table 9.1 List of Profiled Supergeneric Technology Providers
  • Table 9.2 CritiTech (NanOlogy): Pipeline Overview
  • Table 9.3 CritiTech (NanOlogy): Recent Developments and Future Outlook
  • Table 9.4 Crossject: Pipeline Overview
  • Table 9.5 Crossject: Recent Developments and Future Outlook
  • Table 9.6 DelSiTech: Pipeline Overview
  • Table 9.7 DelSiTech: Recent Developments and Future Outlook
  • Table 9.8 Heron Therapeutics: Recent Developments and Future Outlook
  • Table 9.11 Mayne Pharma: Recent Developments and Future Outlook
  • Table 9.12 Neurelis: Pipeline Overview
  • Table 9.13 Taiwan Liposome Company: Pipeline Overview
  • Table 9.14 Taiwan Liposome Company: Recent Developments and Future Outlook
  • Table 10.1 Adverse Events Comparison: Austedo(R) versus Xenazine(R)
  • Table 10.2 Adverse Events Comparison: Abraxane(R) versus Taxol(R)
  • Table 10.3 Adverse Events Comparison: Procysbi(R) versus Cystagon(R)
  • Table 10.4 Adverse Events Comparison: Trokendi XR(R) versus Topiramate IR(R)
  • Table 11.1 Most Likely Candidates for Supergeneric Development
  • Table 11.2 Likely Candidates for Supergeneric Development
  • Table 11.3 Less Likely Candidates for Supergeneric Development
  • Table 11.4 Least Likely Candidates for Supergeneric Development
  • Table 15.1 Impact of Number of Drug Manufacturers on Price of Generic Drugs
  • Table 15.5 Historical Drug Development Costs
  • Table 15.6 Super Generic Drugs: Distribution by Route of Administration
  • Table 15.7 Super Generic Drugs: Distribution by Target Indication
  • Table 15.8 Super Generic Drugs: Distribution by Target Therapeutic Area
  • Table 15.9 Super Generic Drugs: Distribution by Submission Classification Code
  • Table 15.10 Most Active Players: Analysis by Number of Super Generic Drugs
  • Table 15.11 Super Generic Technologies: Distribution by Type of Drug Modification
  • Table 15.12 Super Generic Technologies: Distribution by Type of Technology
  • Table 15.13 Super Generic Technologies: Distribution by Type of Molecules
  • Table 15.14 Super Generic Technologies: Distribution by Route of Administration
  • Table 15.15 Super Generic Technologies: Distribution by Type of Value Addition
  • Table 15.16 Super Generic Technology Developers: Distribution by Year of Establishment
  • Table 15.17 Super Generic Technology Developers: Distribution by Company Size
  • Table 15.18 Super Generic Technology Developers: Distribution by Location of Headquarters (Region)
  • Table 15.20 Most Active Players: Distribution by Number of Super Generic Technologies
  • Table 15.26 Mayne Pharma: Annual Revenues, FY 2019- HI FY 2024 (USD Million)
  • Table 15.27 Taiwan Liposome Company: Annual Revenues, 2014-H1 2019 (NT$ Million)
  • Table 15.28 Revenue Comparison: Xenazine(R) versus Austedo(R) (USD Million)
  • Table 15.29 Annual Revenues: Abraxane(R) 2012-2018 (USD Million)
  • Table 15.30 Annual Revenues: Avycaz(R) 2015-2018 (USD Million)
  • Table 15.31 Annual Revenues: Procysbi(R) 2016-2018 (USD Million)
  • Table 15.32 Annual Revenues: Trokendi XR(R) 2013-2018 (USD Million)
  • Table 15.33 Supergeneric Drugs Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035): Base Scenario (USD Billion)
  • Table 15.34 Super Generics Market: Distribution by Therapeutic Area, 2023 and 2035 (USD Billion)
  • Table 15.35 Super Generics Market: Distribution by Route of Administration, 2023 and 2035 (USD Billion)
  • Table 15.36 Super Generics Market: Distribution by Type of Molecule, 2023 and 2035 (USD Billion)
  • Table 15.37 Super Generics Market: Distribution by Type of Small Molecule, 2023 and 2035 (USD Billion)
  • Table 15.38 Super Generics Market: Distribution by Type of Product, 2023 and 2035 (USD Billion)
  • Table 15.39 Super Generics Market: Distribution by Geography, 2023 and 2035 (USD Billion)
  • Figure 15.40 Supergeneric Drugs Market in North America, 2023-2035 (USD Billion)
  • Table 15.41 Super Generics Market for Oncological Disorders in North America, 2023-2035 (USD Billion)
  • Table 15.42 Super Generics Market for Metabolic Disorders in North America, 2023-2035 (USD Billion)
  • Table 15.43 Super Generics Market for Neurological Disorders in North America, 2023-2035 (USD Billion)
  • Table 15.44 Super Generics Market for Respiratory Disorders in North America, 2023-2035 (USD Billion) (USD Billion)
  • Table 15.45 Super Generics Market for Cardiovascular Disorders in North America, 2023-2035 (USD Billion)
  • Table 15.46 Super Generics Market for Other Disorders in North America, 2023-2035 (USD Billion)
  • Table 15.47 Super Generics Market for Oral Route of Administration in North America, 2023-2035 (USD Billion)
  • Table 15.48 Super Generics Market for Subcutaneous Route of Administration in North America, 2023-2035 (USD Billion)
  • Table 15.49 Super Generics Market for Intravenous Route of Administration in North America, 2023-2035 (USD Billion)
  • Table 15.50 Super Generics Market for Other Routes of Administration in North America, 2023-2035 (USD Billion)
  • Table 15.51 Super Generics Market for Small Molecule in North America, 2023-2035 (USD Billion)
  • Table 15.52 Super Generics Market for Biologics in North America, 2023-2035 (USD Billion)
  • Table 15.53 Super Generics Market for Complex Generics in North America, 2023-2035 (USD Billion)
  • Table 15.54 Super Generics Market for Other Small Molecules in North America, 2023-2035 (USD Billion)
  • Table 15.55 Super Generics Market for Prefilled Syringe in North America, 2023-2035 (USD Billion)
  • Table 15.56 Super Generics Market for Vials in North America, 2023-2035 (USD Billion)
  • Table 15.57 Super Generics Market for Aerosols in North America, 2023-2035 (USD Billion)
  • Table 15.58 Super Generics Market for Tablets in North America, 2023-2035 (USD Billion)
  • Table 15.59 Super Generics Market for Capsules in North America, 2023-2035 (USD Billion)
  • Table 15.60 Super Generics Market for Other Type of Products in North America, 2023-2035 (USD Billion)
  • Table 15.61 Supergeneric Drugs Market in Europe, 2023-2035 (USD Billion)
  • Table 15.62 Super Generics Market for Oncological Disorders in Europe, 2023-2035 (USD Billion)
  • Table 15.63 Super Generics Market for Metabolic Disorders in Europe, 2023-2035 (USD Billion)
  • Table 15.64 Super Generics Market for Neurological Disorders in Europe, 2023-2035 (USD Billion)
  • Table 15.65 Super Generics Market for Respiratory Disorders in Europe, 2023-2035 (USD Billion)
  • Table 15.66 Super Generics Market for Cardiovascular Disorders in Europe, 2023-2035 (USD Billion)
  • Table 15.67 Super Generics Market for Other Disorders in Europe, 2023-2035 (USD Billion)
  • Table 15.68 Super Generics Market for Oral Route of Administration in Europe, 2023-2035 (USD Billion)
  • Table 15.69 Super Generics Market for Subcutaneous Route of Administration in Europe, 2023-2035 (USD Billion)
  • Table 15.70 Super Generics Market for Intravenous Route of Administration in Europe, 2023-2035 (USD Billion)
  • Table 15.71 Super Generics Market for Other Routes of Administration in Europe, 2023-2035 (USD Billion)
  • Table 15.72 Super Generics Market for Small Molecule in Europe, 2023-2035 (USD Billion)
  • Table 15.73 Super Generics Market for Biologics in Europe, 2023-2035 (USD Billion)
  • Table 15.74 Super Generics Market for Complex Generics in Europe, 2023-2035 (USD Billion)
  • Table 15.75 Super Generics Market for Other Small Molecules in Europe, 2023-2035 (USD Billion)
  • Table 15.76 Super Generics Market for Prefilled Syringe in Europe, 2023-2035 (USD Billion)
  • Table 15.77 Super Generics Market for Vials in Europe, 2023-2035 (USD Billion)
  • Table 15.78 Super Generics Market for Aerosols in Europe, 2023-2035 (USD Billion)
  • Table 15.79 Super Generics Market for Tablets in Europe, 2023-2035 (USD Billion)
  • Table 15.80 Super Generics Market for Capsules in Europe, 2023-2035 (USD Billion)
  • Table 15.81 Super Generics Market for Other Type of Products in Europe, 2023-2035 (USD Billion)
  • Table 15.82 Supergeneric Drugs Market in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.83 Super Generics Market for Oncological Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.84 Super Generics Market for Metabolic Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.85 Super Generics Market for Neurological Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.86 Super Generics Market for Respiratory Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.87 Super Generics Market for Cardiovascular Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.88 Super Generics Market for Other Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.89 Super Generics Market for Oral Route of Administration in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.90 Super Generics Market for Subcutaneous Route of Administration in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.91 Super Generics Market for Intravenous Route of Administration in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.92 Super Generics Market for Other Routes of Administration in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.93 Super Generics Market for Small Molecule in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.94 Super Generics Market for Biologics in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.95 Super Generics Market for Complex Generics in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.96 Super Generics Market for Other Small Molecules in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.97 Super Generics Market for Prefilled Syringe in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.98 Super Generics Market for Vials in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.99 Super Generics Market for Aerosols in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.100 Super Generics Market for Tablets in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.101 Super Generics Market for Capsules in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.102 Super Generics Market for Other Type of Products in Asia-Pacific, 2023-2035 (USD Billion)
  • Table 15.103 Supergeneric Drugs Market in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.104 Super Generics Market for Oncological Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.105 Super Generics Market for Metabolic Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.106 Super Generics Market for Neurological Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.107 Super Generics Market for Respiratory Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.108 Super Generics Market for Cardiovascular Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.109 Super Generics Market for Other Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.110 Super Generics Market for Oral Route of Administration in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.111 Super Generics Market for Subcutaneous Route of Administration in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.112 Super Generics Market for Intravenous Route of Administration in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.113 Super Generics Market for Other Routes of Administration in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.114 Super Generics Market for Small Molecule in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.115 Super Generics Market for Biologics in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.116 Super Generics Market for Complex Generics in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.117 Super Generics Market for Other Small Molecules in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.118 Super Generics Market for Prefilled Syringe in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.119 Super Generics Market for Vials in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.120 Super Generics Market for Aerosols in Rest of the World, 2023-2035 (USD Billion)
  • Table 15.121 Super Generics Market for Tablets in Rest of the World, 2023-2035 (USD Billion)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Forecast Methodology
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 2.4 Research Methodology: Key Market Segmentation
  • Figure 3.1 Lessons Learnt from Past Recessions
  • Figure 5.1 Impact of Number of Drug Manufacturers on Price of Generic Drugs
  • Figure 5.2 Advantages Offered by Super Generics
  • Figure 5.3 Historical Drug Development Costs
  • Figure 6.1 Super Generic Drugs: Distribution by Route of Administration
  • Figure 6.2 Super Generic Drugs: Distribution by Target Indication
  • Figure 6.3 Super Generic Drugs: Distribution by Target Therapeutic Area
  • Figure 6.4 Super Generic Drugs: Distribution by Submission Classification Code
  • Figure 6.5 Most Active Players: Distribution by Number of Super Generic Drugs
  • Figure 7.1 Super Generic Technologies: Distribution by Type of Drug Modification
  • Figure 7.2 Super Generic Technologies: Distribution by Type of Technology
  • Figure 7.3 Super Generic Technologies: Distribution by Type of Molecules
  • Figure 7.4 Super Generic Technologies: Distribution by Route of Administration
  • Figure 7.5 Super Generic Technologies: Distribution by Type of Value Addition
  • Figure 7.6 Super Generic Technology Providers: Distribution by Year of Establishment
  • Figure 7.7 Super Generic Technology Providers: Distribution by Company Size
  • Figure 7.8. Super Generic Technology Providers: Distribution by Location of Headquarters (Region)
  • Figure 7.9. Most Active Players: Distribution by Number of Super Generic Technologies
  • Figure 8.1 Technology Competitiveness Analysis: Technologies Offered by Companies based in North America (Peer Group I)
  • Figure 8.2 Technology Competitiveness Analysis: Technologies Offered by Companies based in North America (Peer Group II)
  • Figure 8.3 Technology Competitiveness Analysis: Technologies Offered by Companies based in Europe
  • Figure 8.4 Technology Competitiveness Analysis: Technologies Offered by Companies based in Asia-Pacific
  • Figure 9.1 Ascendia Pharmaceuticals: Technology Portfolio
  • Figure 9.2 CritiTech: Technology Portfolio
  • Figure 9.3 Intellipharmaceutics International: Annual Revenues, 2013- H1 2019 (USD Million)
  • Figure 9.6 LATITUDE Pharmaceuticals: Technology Portfolio
  • Figure 9.7 Mayne Pharma: Annual Revenues, FY 2019-HI FY 2024 (USD Million)
  • Figure 9.8 Mayne Pharma: Technology Portfolio
  • Figure 9.9 Rubicon Research: Technology Portfolio
  • Figure 9.10 Taiwan Liposome Company: Annual Revenues, 2014-H1 2019 (NT$ Million)
  • Figure 9.11 Taiwan Liposome Company: Technology Portfolio
  • Figure 9.12 tesa Labtec: Technology Portfolio
  • Figure 10.1 Austedo(R): Development Timeline
  • Figure 10.2 Revenue Comparison: Xenazine(R) versus Austedo(R) (USD Million)
  • Figure 10.3 Abraxane(R): Development Timeline
  • Figure 10.4 Revenue Comparison: Taxol(R) versus Abraxane(R) (USD Million)
  • Figure 10.5 Annual Revenues: Abraxane(R) 2012-2018 (USD Million)
  • Figure 10.6 Avycaz(R): Development Timeline
  • Figure 10.7 Annual Revenues: Avycaz(R) 2015-2018 (USD Million)
  • Figure 10.8 Procysbi(R): Development Timeline
  • Figure 10.9 Annual Revenues: Procysbi(R) 2016-2018 (USD Million)
  • Figure 10.10 Trokendi XR(R): Development Timeline
  • Figure 10.11 Annual Revenues: Trokendi XR(R) 2013-2018 (USD Million)
  • Figure 12.1 Super Generics: SWOT Analysis
  • Figure 12.2 Comparison of SWOT Factors: Harvey Ball Analysis
  • Figure 13.1 Supergeneric Drugs Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035): Base Scenario (USD Billion)
  • Figure 13.2 Super Generics Market: Distribution by Therapeutic Area, 2023 and 2035 (USD Billion)
  • Figure 13.3 Super Generics Market: Distribution by Route of Administration, 2023 and 2035 (USD Billion)
  • Figure 13.4 Super Generics Market: Distribution by Type of Molecule, 2023 and 2035 (USD Billion)
  • Figure 13.5 Super Generics Market: Distribution by Type of Small Molecule, 2023 and 2035 (USD Billion)
  • Figure 13.6 Super Generics Market: Distribution by Type of Product, 2023 and 2035 (USD Billion)
  • Figure 13.7 Super Generics Market: Distribution by Geography, 2023 and 2035 (USD Billion)
  • Figure 13.8 Supergeneric Drugs Market in North America, 2023-2035 (USD Billion)
  • Figure 13.9 Super Generics Market for Oncological Disorders in North America, 2023-2035 (USD Billion)
  • Figure 13.10 Super Generics Market for Metabolic Disorders in North America, 2023-2035 (USD Billion)
  • Figure 13.11 Super Generics Market for Neurological Disorders in North America, 2023-2035 (USD Billion)
  • Figure 13.12 Super Generics Market for Respiratory Disorders in North America, 2023-2035 (USD Billion) (USD Billion)
  • Figure 13.13 Super Generics Market for Cardiovascular Disorders in North America, 2023-2035 (USD Billion)
  • Figure 13.14 Super Generics Market for Other Disorders in North America, 2023-2035 (USD Billion)
  • Figure 13.15 Super Generics Market for Oral Route of Administration in North America, 2023-2035 (USD Billion)
  • Figure 13.16 Super Generics Market for Subcutaneous Route of Administration in North America, 2023-2035 (USD Billion)
  • Figure 13.17 Super Generics Market for Intravenous Route of Administration in North America, 2023-2035 (USD Billion)
  • Figure 13.18 Super Generics Market for Other Routes of Administration in North America, 2023-2035 (USD Billion)
  • Figure 13.19 Super Generics Market for Small Molecule in North America, 2023-2035 (USD Billion)
  • Figure 13.20 Super Generics Market for Biologics in North America, 2023-2035 (USD Billion)
  • Figure 13.21 Super Generics Market for Complex Generics in North America, 2023-2035 (USD Billion)
  • Figure 13.22 Super Generics Market for Other Small Molecules in North America, 2023-2035 (USD Billion)
  • Figure 13.23 Super Generics Market for Prefilled Syringe in North America, 2023-2035 (USD Billion)
  • Figure 13.24 Super Generics Market for Vials in North America, 2023-2035 (USD Billion)
  • Figure 13.25 Super Generics Market for Aerosols in North America, 2023-2035 (USD Billion)
  • Figure 13.26 Super Generics Market for Tablets in North America, 2023-2035 (USD Billion)
  • Figure 13.27 Super Generics Market for Capsules in North America, 2023-2035 (USD Billion)
  • Figure 13.28 Super Generics Market for Other Type of Products in North America, 2023-2035 (USD Billion)
  • Figure 13.29 Supergeneric Drugs Market in Europe, 2023-2035 (USD Billion)
  • Figure 13.30 Super Generics Market for Oncological Disorders in Europe, 2023-2035 (USD Billion)
  • Figure 13.31 Super Generics Market for Metabolic Disorders in Europe, 2023-2035 (USD Billion)
  • Figure 13.32 Super Generics Market for Neurological Disorders in Europe, 2023-2035 (USD Billion)
  • Figure 13.33 Super Generics Market for Respiratory Disorders in Europe, 2023-2035 (USD Billion)
  • Figure 13.34 Super Generics Market for Cardiovascular Disorders in Europe, 2023-2035 (USD Billion)
  • Figure 13.35 Super Generics Market for Other Disorders in Europe, 2023-2035 (USD Billion)
  • Figure 13.36 Super Generics Market for Oral Route of Administration in Europe, 2023-2035 (USD Billion)
  • Figure 13.37 Super Generics Market for Subcutaneous Route of Administration in Europe, 2023-2035 (USD Billion)
  • Figure 13.38 Super Generics Market for Intravenous Route of Administration in Europe, 2023-2035 (USD Billion)
  • Figure 13.39 Super Generics Market for Other Routes of Administration in Europe, 2023-2035 (USD Billion)
  • Figure 13.40 Super Generics Market for Small Molecule in Europe, 2023-2035 (USD Billion)
  • Figure 13.41 Super Generics Market for Biologics in Europe, 2023-2035 (USD Billion)
  • Figure 13.42 Super Generics Market for Complex Generics in Europe, 2023-2035 (USD Billion)
  • Figure 13.43 Super Generics Market for Other Small Molecules in Europe, 2023-2035 (USD Billion)
  • Figure 13.44 Super Generics Market for Prefilled Syringe in Europe, 2023-2035 (USD Billion)
  • Figure 13.45 Super Generics Market for Vials in Europe, 2023-2035 (USD Billion)
  • Figure 13.46 Super Generics Market for Aerosols in Europe, 2023-2035 (USD Billion)
  • Figure 13.47 Super Generics Market for Tablets in Europe, 2023-2035 (USD Billion)
  • Figure 13.48 Super Generics Market for Capsules in Europe, 2023-2035 (USD Billion)
  • Figure 13.49 Super Generics Market for Other Type of Products in Europe, 2023-2035 (USD Billion)
  • Figure 13.50 Supergeneric Drugs Market in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.51 Super Generics Market for Oncological Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.52 Super Generics Market for Metabolic Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.53 Super Generics Market for Neurological Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.54 Super Generics Market for Respiratory Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.55 Super Generics Market for Cardiovascular Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.56 Super Generics Market for Other Disorders in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.57 Super Generics Market for Oral Route of Administration in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.58 Super Generics Market for Subcutaneous Route of Administration in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.59 Super Generics Market for Intravenous Route of Administration in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.60 Super Generics Market for Other Routes of Administration in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.61 Super Generics Market for Small Molecule in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.62 Super Generics Market for Biologics in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.63 Super Generics Market for Complex Generics in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.64 Super Generics Market for Other Small Molecules in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.65 Super Generics Market for Prefilled Syringe in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.66 Super Generics Market for Vials in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.67 Super Generics Market for Aerosols in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.68 Super Generics Market for Tablets in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.69 Super Generics Market for Capsules in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.70 Super Generics Market for Other Type of Products in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 13.71 Supergeneric Drugs Market in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.72 Super Generics Market for Oncological Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.73 Super Generics Market for Metabolic Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.74 Super Generics Market for Neurological Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.75 Super Generics Market for Respiratory Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.76 Super Generics Market for Cardiovascular Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.77 Super Generics Market for Other Disorders in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.78 Super Generics Market for Oral Route of Administration in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.79 Super Generics Market for Subcutaneous Route of Administration in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.80 Super Generics Market for Intravenous Route of Administration in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.81 Super Generics Market for Other Routes of Administration in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.82 Super Generics Market for Small Molecule in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.83 Super Generics Market for Biologics in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.84 Super Generics Market for Complex Generics in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.85 Super Generics Market for Other Small Molecules in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.86 Super Generics Market for Prefilled Syringe in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.87 Super Generics Market for Vials in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.88 Super Generics Market for Aerosols in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.89 Super Generics Market for Tablets in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.90 Super Generics Market for Capsules in Rest of the World, 2023-2035 (USD Billion)
  • Figure 13.91 Super Generics Market for Other Type of Products in Rest of the World, 2023-2035 (USD Billion)
  • Figure 14.1 Concluding Remarks: Super Generics Drugs Market Landscape